Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$561.94
-0.2%
$569.33
$457.42
$678.21
$34.26B0.37332,308 shs121,155 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$82.85
-1.4%
$79.07
$73.31
$129.93
$207.81B0.3913.37 million shs3.93 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$25.44
-1.7%
$22.74
$8.24
$36.91
$18.89B-1.013.73 million shs762,761 shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$14.65
-1.3%
$14.85
$12.80
$15.53
$46.60B0.232.00 million shs1.45 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+1.46%+3.68%-2.11%-3.03%+20.56%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.38%+3.82%+3.37%+6.22%-33.98%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+4.61%+6.31%+17.21%+11.36%+212.18%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
-2.08%-4.66%-2.82%+6.65%+11.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
argenex SE stock logo
ARGX
argenex
4.4484 of 5 stars
4.53.00.00.03.11.72.5
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.9977 of 5 stars
3.23.05.04.23.42.53.8
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.3805 of 5 stars
4.41.00.00.01.41.70.0
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
1.4908 of 5 stars
0.03.02.50.03.20.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
3.10
Buy$728.0630.58% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.43
Hold$108.6931.79% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.79
Moderate Buy$34.6736.32% Upside
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest SMMT, MRK, TAK, and ARGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$99.00 ➝ $98.00
7/8/2025
argenex SE stock logo
ARGX
argenex
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
7/3/2025
argenex SE stock logo
ARGX
argenex
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$700.00
7/1/2025
argenex SE stock logo
ARGX
argenex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$720.00
7/1/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$44.00
7/1/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/24/2025
argenex SE stock logo
ARGX
argenex
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$715.00
6/11/2025
argenex SE stock logo
ARGX
argenex
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$715.00
6/11/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell
6/11/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderperform$12.00
6/10/2025
argenex SE stock logo
ARGX
argenex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$720.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$2.25B15.12$2.98 per share186.90$90.49 per share6.16
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.23$9.33 per share8.84$18.33 per share4.50
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.53 per shareN/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$30.09B1.55$3.08 per share4.76$14.39 per share1.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$833.04M$16.2134.5051.391.0240.20%16.15%14.33%7/24/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.8712.018.330.8727.27%43.23%17.11%7/29/2025 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$221.32M-$0.34N/AN/AN/AN/A-62.87%-51.61%8/5/2025 (Estimated)
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$712.33M$0.2266.578.87N/A2.36%10.64%5.14%7/30/2025 (Estimated)

Latest SMMT, MRK, TAK, and ARGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.10N/AN/AN/AN/AN/A
7/30/2025Q1 2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.47N/AN/AN/A$7.96 billionN/A
7/29/2025Q2 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.03N/AN/AN/A$15.92 billionN/A
7/24/2025Q2 2025
argenex SE stock logo
ARGX
argenex
$2.87N/AN/AN/A$776.82 millionN/A
5/8/2025Q1 2025
argenex SE stock logo
ARGX
argenex
$2.32$2.58+$0.26$2.58$748.34 million$1.35 billion
5/8/2025Q4 2025
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.24$0.16-$0.08-$0.21$8.02 billion$7.34 billion
5/1/2025Q1 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.10-$0.09+$0.01-$0.09N/AN/A
4/24/2025Q1 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.16$2.22+$0.06$2.01$15.59 billion$15.53 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.243.93%N/A47.16%14 Years
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.553.76%N/A250.00%N/A

Latest SMMT, MRK, TAK, and ARGX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/27/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.814.18%6/16/20256/16/20257/8/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
7.29
6.68
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.69
1.41
1.16
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
10.63
10.63
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.57
1.01
0.52

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
9.17%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.13%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
84.90%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.04%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,59961.06 million59.58 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.51 billion2.51 billionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
110742.67 million112.14 millionOptionable
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
47,4553.18 billion3.18 billionOptionable

Recent News About These Companies

Takeda: Positives And Negatives Offset Each Other
Lupin gets USFDA approval for post-eye surgery drug
FDA Approves Takeda’s Gammagard Liquid ERC
Lupin receives USFDA approval for Prucalopride Tablets
Takeda Announces New Assignments of Directors

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
argenex stock logo

argenex NASDAQ:ARGX

$561.94 -1.37 (-0.24%)
As of 12:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$82.85 -1.17 (-1.40%)
As of 12:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$25.44 -0.44 (-1.70%)
As of 12:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Takeda Pharmaceutical stock logo

Takeda Pharmaceutical NYSE:TAK

$14.64 -0.20 (-1.31%)
As of 12:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.